• PolyPid’s third-quarter 2026 net loss narrowed 23% year over year to $5.75 million.
• Research and development expenses rose 24% to $6.52 million due to NDA-related activities and commercial readiness preparations.
• A $15 million post-quarter Azurity payment strengthened liquidity; management expects cash and anticipated proceeds to fund operations into 2028.
• D-PLEX₁₀₀ has a November 28, 2026, FDA decision target, with a potential U.S. launch in early 2027, subject to approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PolyPid Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611110730PRIMZONEFULLFEED9874606) on November 11, 2026, and is solely responsible for the information contained therein.